Document Detail


Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
MedLine Citation:
PMID:  11583728     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cilostazol, a novel oral phosphodiesterase inhibitor, has shown consistent improvement in exercise tolerance in patients with intermittent claudication (IC). In addition to this effect, cilostazol has previously been shown to have beneficial effects on the dyslipidemia, i.e., combination of high triglycerides with low high-density-lipoprotein cholesterol (HDL-C) levels. Interleukin-6 (IL-6) suppresses the activity of lipoprotein lipase, which modulates the metabolism of triglycerides and HDL-C. To determine whether a reduction of IL-6 contributes to the improvement of lipid profiles, we prospectively investigated the effect of cilostazol (n=16, 100 mg, twice daily) on the changes of lipid profiles and on the association with the changes of IL-6 compared with those of pentoxifylline (n=16, 400 mg, bid) in patients with IC. After eight weeks of administration of cilostazol to patients with IC, walking distances were increased, associated with a 29% decrease in plasma triglycerides and a 13% increase in HDL-C. No significant changes of lipid profiles in the pentoxifylline and placebo groups were observed although a similar improvement in walking distances was achieved in the pentoxifylline group. IL-6 levels were significantly reduced in patients receiving cilostazol as compared with those receiving placebo or pentoxifylline. The cilostazol-induced changes in the IL-6 were positively related to those of triglycerides in the cilostazol group (r=0.63, P<0.05) and negatively related to those of HDL-C (r=-0.55, P<0.05). These findings suggest that in addition to consistent improvement of exercise tolerance, cilostazol may improve lipid profiles by reducing IL-6 release. However, pentoxifylline did not affect lipid profiles although a similar improvement of maximal walking distance (MWD) was achieved.
Authors:
T M Lee; S F Su; J J Hwang; C D Tseng; M F Chen; Y T Lee; S S Wang
Related Documents :
18784538 - Changing clinical profile of patients entering cardiac rehabilitation/secondary prevent...
12241128 - Oxidation injury in patients receiving hmg-coa reductase inhibitors: occurrence in pati...
17598368 - Beneficial effect of low-density lipoprotein apheresis (ldl-a) on refractory nephrotic ...
7830728 - Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patie...
17453148 - Discovery of serum biomarkers in astrocytoma by seldi-tof ms and proteinchip technology.
9972768 - Anesthesia for intranasal surgery: a comparison between tracheal intubation and the fle...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Atherosclerosis     Volume:  158     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-03     Completed Date:  2002-01-22     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  471-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Cardiology Section, National Taiwan University Hospital, 7, Chung-Shan S. RD., Taipei, 10002, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cholesterol / blood
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Double-Blind Method
Enzyme Inhibitors / therapeutic use*
Female
Humans
Hypolipidemic Agents / therapeutic use*
Interleukin-6 / blood*,  physiology
Intermittent Claudication / blood*,  drug therapy
Lipids / blood*
Male
Pentoxifylline / therapeutic use*
Phosphodiesterase Inhibitors / therapeutic use*
Prospective Studies
Tetrazoles / therapeutic use*
Triglycerides / blood
Vasodilator Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Enzyme Inhibitors; 0/Hypolipidemic Agents; 0/Interleukin-6; 0/Lipids; 0/Phosphodiesterase Inhibitors; 0/Tetrazoles; 0/Triglycerides; 0/Vasodilator Agents; 57-88-5/Cholesterol; 6493-05-6/Pentoxifylline; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship between response of gamma-glutamyl transpeptidase to alcohol drinking and risk factors ...
Next Document:  Increased leukocyte activity as a predictor for flow-limiting coronary lesions in patients with angi...